MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

Pathologic re-review of NMIBC surgical specimens by genitourinary pathologists led to a change in risk stratification in one-fifth of cases. Pathologic re-review of transurethral resection of bladder ...

Meanwhile, the incidence of cancer diagnoses in older adults continues to increase, especially in genitourinary (GU) cancers (prostate cancer, bladder cancer, and kidney cancer). As a result, there is ...

Designing and Validating a Comprehensive Patient-Reported Outcomes Measure for Ambulatory Cancer Settings: The Revised Edmonton Symptom Assessment System for Cancer We retrospectively analyzed ...

FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO ® 2026 ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

Genitourinary cancers include prostate, bladder, kidney, and testicular cancers, with diagnosis involving imaging and biopsy. Treatment is personalized, involving surgery, radiation, chemotherapy, ...

Cross-referencing protocols/registries with publications revealed substantial attrition from planned QoL endpoints to disseminated results across prostate, kidney, and bladder cancer trials. Selective ...

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...

This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...